Back to search

Article

Novel genomic variants influencing methotrexate delayed excretion in pediatric patients with acute lymphoblastic leukemia

2024-03-06

Abstract excerpt

<h4>Background: </h4> Methotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed excretion of high-dose (HD) MTX, which induces severe nephrotoxicity. We sought to identify relevant mutations associated with delayed excretion of HD-MTX in pediatric patients with ALL. Methods Whole-exome sequencing of germline DNA was perform...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64031ccd-2936-5bce-a394-66c87ee3ba24
DOI
10.21203/rs.3.rs-4007463/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel genomic variants influencing methotrexate delayed excretion in pediatric patients with acute lymphoblastic leukemiaDOI 10.21203/rs.3.rs-4007463/v1
Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.Semantic proximity
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy on prognosis of childhood acute lymphoblastic leukemiaSemantic proximity
Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia.Semantic proximity
Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.Semantic proximity
The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity
Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.Semantic proximity
Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Semantic proximity
Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Semantic proximity
Association of SLC19A1 Gene Polymorphisms and Its Regulatory miRNAs with Methotrexate Toxicity in Children with Acute Lymphoblastic LeukemiaSemantic proximity
Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia.Semantic proximity
NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine TherapySemantic proximity
Select a neighboring publication to make it the new centre.